Kardigan, Inc. Common Stock (KARD) - Total Liabilities
Based on the latest financial reports, Kardigan, Inc. Common Stock (KARD) has total liabilities worth $648.82 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Kardigan, Inc. Common Stock (KARD) net asset momentum to track the company's year-over-year net asset growth rate.
Kardigan, Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Kardigan, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Kardigan, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Kardigan, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Omnicell Inc
NASDAQ:OMCL
|
USA | $742.91 Million |
|
Allied Blenders & Distillers Ltd
NSE:ABDL
|
India | Rs19.72 Billion |
|
Homeco Daily Needs REIT
AU:HDN
|
Australia | AU$1.89 Billion |
|
AG Anadolu Group Holding
IS:AGHOL
|
Turkey | TL348.37 Billion |
|
Beijing Dabeinong Technology Group Co Ltd
SHE:002385
|
China | CN¥19.82 Billion |
|
Isrotel -L
TA:ISRO
|
Israel | ILA2.62 Billion |
|
BaoJi Titanium Industry Co Ltd
SHG:600456
|
China | CN¥7.45 Billion |
|
Zhejiang Jinke Peroxides Co Ltd
SHE:300459
|
China | CN¥1.68 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down Kardigan, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Kardigan, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.86 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kardigan, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kardigan, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Kardigan, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $641.28 Million | +337.08% |
| 2024-12-31 | $146.72 Million | -- |
About Kardigan, Inc. Common Stock
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI… Read more